Conventional antipsychotic prescription in unipolar depression, II: Withdrawing conventional antipsychotics in unipolar, nonpsychotic patients

Journal of Clinical Psychiatry

Volumn 64, Issue 6, 2003, Pages 668-672

  Mortimer, Ann M ^a   Martin, Maria ^b   Wheeler Vega, Jason A ^c   Tyson, Philip J ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b Clinical Psychology Service for Older People   (United States)

^c NEW SCHOOL FOR SOCIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; PERGOLIDE; PERGOLIDE MESILATE; PRAMIPEXOLE;

ADULT; ARTICLE; CLINICAL FEATURE; COMORBIDITY; DAILY LIFE ACTIVITY; DISEASE DURATION; DOPAMINERGIC ACTIVITY; DRUG EFFECT; DRUG INDICATION; DRUG UTILIZATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; INVOLUNTARY MOVEMENT; LONG TERM CARE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICAL AUDIT; MOTOR DYSFUNCTION; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; RATING SCALE; RISK ASSESSMENT; SYMPTOM;

EID: 0037591522     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v64n0608     Document Type: Article

References (28)

1. Wheeler Vega JA, Mortimer AM, Tyson PJ. Conventional antipsychotic prescription in unipolar depression, 1: an audit and recommendations for practice. J Clin Psychiatry 2003;64:568-574
2. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812
3. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296
4. Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry 1988;39: 1172-1177
5. Munetz MR, Benjamin S. CMHC practices related to tardive dyskinesia screening and informed consent for neuroleptic drugs. Hosp Community Psychiatry 1994;45:343-346
6. Wallace CJ, Liberman RP, Tauber R, et al. The Independent Living Skills Survey: a comprehensive measure of the community functioning of severely and persistently mentally ill individuals. Schizophr Bull 2000; 26:631-658
7. Joint Formulary Committee. British National Formulary. 45th ed. London, England: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2003
8. Overall JE. The Brief Psychiatic Rating Scale in psychopharmacologic research. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976: 166-169
9. de Montigny C, Cournoyer G, Morissete R. Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression. Arch Gen Psychiatry 1983;40:1327-1334
10. Reynolds CF, Frank E, Perel JM. High relapse rate after discontinuation of adjunctive medication for elderly patients with recurrent major depression. Am J Psychiatry 1996;153:1418-1422
11. Wheeler Vega JA, Mortimer AM, Tyson PJ. Somatic treatment of psychotic depression: review and recommendations for practice. J Clin Psychopharmacol 2000;20:504-519
12. Fava M. Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry 2001;62(suppl 18):4-11
13. Ohaeri JU. Naturalistic study of olanzapine in treatment-resistant schizophrenia and acute mania, depression and obsessional disorder. East Afr Med J 2000;77:86-92
14. Ghaemi SN, Cherry EL, Katzow JA, et al. Does olanzapine have antidepressant properties? a retrospective preliminary study. Bipolar Disord 2000;2:196-199
15. Bressan RA, Costa DC, Jones HM, et al. Typical antipsychotic drugs: D(2) receptor occupancy and depressive symptoms in schizophrenia. Schizophr Res 2002;56:31-36
16. Fava M. Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry 2001;62(suppl 18):4-11.
17. Bouckoms A, Mangini L. Pergolide: an antidepressant adjuvant for mood disorders? Psychopharmacol Bull 1993;29:207-211
18. Izumi T, Inoue T, Kitagawa N, et al. Open pergolide treatment of tricyclic and heterocyclic antidepressant-resistant depression. J Affect Disord 2000;61:127-132
19. Michelson D, Bancroft J, Targum S. Female sexual dysfunction associated with antidepressant administration: a randomized, placebo-controlled trial of pharmacologic intervention. Am J Psychiatry 2000;157:239-243
20. Mattes JA. Pergolide to augment the effectiveness of antidepressants: clinical experience and a small double-blind study. Ann Clin Psychiatry 1997;9:87-88
21. Lattanzi L, Cassano P, Dell'Osso L. Adjunctive pramipexole in treatment resistant depression. Presented at the 39th annual meeting of the American College of Neuropsychopharmacology; Dec 10-14, 2000; San Juan, Puerto Rico
22. Sporn J, Ghaemi SN, Sambur MR, et al. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann Clin Psychiatry 2000;12:137-140
23. Corrigan MH, Denahan AQ, Wright CE, et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000;11:58-65
24. McErlain-Burns TL, Thomson R. The lack of integration of clinical audit and the maintenance of medical dominance within British hospital trusts. J Eval Clin Pract 1999;5:323-333
25. Johnston G, Crombie IK, Davies HT, et al. Reviewing audit: barriers and facilitating factors for effective clinical audit. Qual Health Care 2000;9: 23-36
26. Weiss KB, Wagner R. Performance measurement through audit, feedback and profiling as tools for improving clinical care. Chest 2000;118:53-58
27. Thomson O'Brien MA, Oxman AD, Davis DA, et al. Audit and feedback: effects on professional practice and health care outcomes. Cochrane Database of Systematic Reviews (2): CD000259; 2000
28. Thomson O'Brien MA, Oxman AD, Davis DA, et al. Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database of Systematic Reviews (2): CD000409; 2000